Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least ...
Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug's commercial potentialIn September 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback